Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -657.26 Million CAD | 80.14% |
| 2022 | -3.3 Billion USD | -932.67% |
| 2021 | -320.48 Million CAD | 80.82% |
| 2020 | -1.67 Billion CAD | -20.42% |
| 2019 | -1.38 Billion CAD | -107.05% |
| 2018 | -670.09 Million CAD | -1137.84% |
| 2017 | -54.13 Million CAD | -225.97% |
| 2016 | -16.6 Million CAD | -375.03% |
| 2015 | -3.49 Million CAD | 60.86% |
| 2014 | -8.93 Million CAD | -857.35% |
| 2013 | -932.92 Thousand CAD | -1343.98% |
| 2012 | -64.6 Thousand CAD | -202.01% |
| 2011 | -21.39 Thousand CAD | 11.11% |
| 2010 | -24.06 Thousand CAD | 10.59% |
| 2009 | -26.91 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -92.89 Million USD | -37.69% |
| 2023 Q3 | -216.79 Million USD | 30.07% |
| 2023 FY | -657.26 Million USD | 80.14% |
| 2023 Q1 | -38.12 Million USD | 94.11% |
| 2023 Q2 | -310.01 Million USD | -713.24% |
| 2023 Q4 | -68.16 Million USD | 68.56% |
| 2022 Q3 | -266.72 Million CAD | -15.01% |
| 2022 FY | -3.3 Billion USD | -932.67% |
| 2022 Q1 | -2.08 Billion CAD | -260.79% |
| 2022 Q4 | -647.6 Million USD | -142.8% |
| 2022 Q2 | -231.91 Million CAD | 88.89% |
| 2021 Q1 | 392.41 Million CAD | 156.06% |
| 2021 Q2 | -11.05 Million CAD | -102.82% |
| 2021 Q3 | -115.49 Million CAD | -944.46% |
| 2021 Q4 | -578.61 Million CAD | -400.98% |
| 2021 FY | -320.48 Million CAD | 80.82% |
| 2020 Q2 | -32.06 Million CAD | 70.45% |
| 2020 Q3 | -904.38 Million CAD | -2720.81% |
| 2020 Q4 | -699.97 Million CAD | 22.6% |
| 2020 Q1 | -108.5 Million CAD | -123.75% |
| 2020 FY | -1.67 Billion CAD | -20.42% |
| 2019 Q2 | -374.18 Million CAD | 70.84% |
| 2019 Q1 | -1.28 Billion CAD | -282.31% |
| 2019 Q4 | 456.88 Million CAD | 477.69% |
| 2019 FY | -1.38 Billion CAD | -107.05% |
| 2019 Q3 | -120.96 Million CAD | 67.67% |
| 2018 FY | -670.09 Million CAD | -1137.84% |
| 2018 Q1 | -80.27 Million CAD | -30.44% |
| 2018 Q2 | -337.13 Million CAD | -319.97% |
| 2018 Q3 | 67.58 Million CAD | 120.05% |
| 2018 Q4 | -335.6 Million CAD | -596.59% |
| 2017 FY | -54.13 Million CAD | -225.97% |
| 2017 Q4 | -61.54 Million CAD | -3987.81% |
| 2017 Q3 | 1.58 Million CAD | 218.31% |
| 2017 Q2 | -1.33 Million CAD | 69.06% |
| 2017 Q1 | -4.32 Million CAD | 79.49% |
| 2016 FY | -16.6 Million CAD | -375.03% |
| 2016 Q4 | -21.08 Million CAD | -804.55% |
| 2016 Q2 | 5.43 Million CAD | 237.5% |
| 2016 Q1 | -3.94 Million CAD | 22.9% |
| 2016 Q3 | 2.99 Million CAD | -44.9% |
| 2015 Q4 | -5.12 Million CAD | -54.46% |
| 2015 FY | -3.49 Million CAD | 60.86% |
| 2015 Q3 | -3.31 Million CAD | -184.39% |
| 2015 Q2 | 3.92 Million CAD | 288.38% |
| 2015 Q1 | 1.01 Million CAD | 177.72% |
| 2014 Q1 | -1.16 Million CAD | 57.9% |
| 2014 FY | -8.93 Million CAD | -857.35% |
| 2014 Q4 | -1.3 Million CAD | 50.66% |
| 2014 Q3 | -2.63 Million CAD | -11.01% |
| 2014 Q2 | -2.37 Million CAD | -104.82% |
| 2013 Q2 | -7269.00 CAD | 80.75% |
| 2013 Q3 | -28.19 Thousand CAD | -287.92% |
| 2013 FY | -932.92 Thousand CAD | -1343.98% |
| 2013 Q4 | -2.75 Million CAD | -9674.74% |
| 2013 Q1 | -37.75 Thousand CAD | -667.75% |
| 2012 Q4 | -4918.00 CAD | 58.76% |
| 2012 Q1 | -2448.00 CAD | 67.59% |
| 2012 Q2 | -20.89 Thousand CAD | -753.59% |
| 2012 Q3 | -11.92 Thousand CAD | 42.93% |
| 2012 FY | -64.6 Thousand CAD | -202.01% |
| 2011 Q4 | -7554.00 CAD | 15.92% |
| 2011 Q3 | -8984.00 CAD | -273.09% |
| 2011 Q1 | -377.00 CAD | 95.01% |
| 2011 FY | -21.39 Thousand CAD | 11.11% |
| 2011 Q2 | -2408.00 CAD | -538.73% |
| 2010 Q4 | -7548.00 CAD | 43.0% |
| 2010 Q3 | -13.24 Thousand CAD | -356.66% |
| 2010 Q2 | -2900.00 CAD | -2001.45% |
| 2010 Q1 | -138.00 CAD | 98.43% |
| 2010 FY | -24.06 Thousand CAD | 10.59% |
| 2009 FY | -26.91 Thousand CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | -18 Thousand CAD | 0.0% |
| 2009 Q4 | -8777.00 CAD | 51.25% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Theratechnologies Inc. | -23.95 Million USD | -2643.536% |
| Harrow Health, Inc. | -24.41 Million USD | -2592.512% |
| Dynavax Technologies Corporation | -6.38 Million USD | -10187.51% |
| Biofrontera Inc. | -20.13 Million USD | -3164.96% |
| Cronos Group Inc. | -73.96 Million USD | -788.646% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -13493.981% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 34.42% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -1457.546% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 2848.24% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -10367.2% |
| Radius Health, Inc. | -25.79 Million USD | -2448.443% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -10564.652% |
| DURECT Corporation | -27.62 Million USD | -2279.34% |
| ProPhase Labs, Inc. | -16.78 Million USD | -3816.512% |
| Safety Shot Inc | -15.08 Million USD | -4257.669% |
| Phibro Animal Health Corporation | 2.41 Million USD | 27304.843% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -21112.271% |
| Alvotech | -551.73 Million USD | -19.129% |
| Assertio Holdings, Inc. | -331.94 Million USD | -98.007% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 50044.453% |
| Rockwell Medical, Inc. | -8.43 Million USD | -7688.47% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -14486.387% |
| Procaps Group S.A. | 42.54 Million USD | 1645.061% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | -370.574% |
| SCYNEXIS, Inc. | 67.04 Million USD | 1080.399% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -4048.378% |
| Viatris Inc. | 54.7 Million USD | 1301.589% |
| OptiNose, Inc. | -35.48 Million USD | -1752.349% |
| SIGA Technologies, Inc. | 68.06 Million USD | 1065.595% |
| Tilray Brands, Inc. | -244.98 Million USD | -168.294% |
| PetIQ, Inc. | 2.13 Million USD | 30943.219% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -14486.387% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 363.223% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 416006.171% |
| Alimera Sciences, Inc. | -20.13 Million USD | -3164.797% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 1464.903% |
| Silver Spike Investment Corp. | 7.34 Million USD | 9054.487% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -9869.613% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 13391.587% |
| Journey Medical Corporation | -3.85 Million USD | -16958.63% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -7951.621% |
| Alpha Teknova, Inc. | -36.78 Million USD | -1687.028% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -3572.099% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 5571.314% |
| PainReform Ltd. | -9.34 Million USD | -6934.129% |
| Cosmos Health Inc. | -18.54 Million USD | -3444.633% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | -310.086% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -6294.911% |
| Embecta Corp. | 70.4 Million USD | 1033.621% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -15178.798% |
| Talphera, Inc. | -18.39 Million USD | -3472.697% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 1666.605% |
| Incannex Healthcare Limited | -18.45 Million USD | -3460.697% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -3176.956% |
| Shineco, Inc. | -22.44 Million USD | -2827.83% |
| Procaps Group, S.A. | 42.54 Million USD | 1645.061% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 3600.021% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -8251.576% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 301.208% |
| Alvotech | -551.73 Million USD | -19.129% |
| Hempacco Co., Inc. | -13.12 Million USD | -4907.351% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 1944.086% |
| Bright Green Corporation | -13.12 Million USD | -4906.754% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -214.11% |
| Kamada Ltd. | 8.28 Million USD | 8034.198% |
| Indivior PLC | 2 Million USD | 32963.45% |
| Evoke Pharma, Inc. | -7.79 Million USD | -8334.858% |
| Flora Growth Corp. | -57.03 Million USD | -1052.376% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -3176.956% |
| Evolus, Inc. | -61.68 Million USD | -965.525% |
| HUTCHMED (China) Limited | 100.78 Million USD | 752.182% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 577.857% |
| Akanda Corp. | -32.27 Million USD | -1936.46% |